Abstract
Introduction
The first documented cases of acquired immunodeficiency syndrome (AIDS), which is caused by the human immunodeficiency virus (HIV), were described in 1981 . The World Health Organization has estimated that the combined number of cases of HIV infection and AIDS will reach 40 million in 2000. 1 With the increasing prevalence of HIV infection and AIDS, it is essential that otolaryngologists be aware of the ENT manifestations of HIV infection. Otolaryngologists can play an important role in the care of HIV patients and are often asked to evaluate them. The otolaryngologic manifestations of AIDS are varied; they include otorrhea, hearing loss, otitis media and externa, rhinologic symptoms (including sinusitis), nasopharyngeal masses, parotid cysts, and cervical lymphadenopathy, as well as other manifestations of conditions unique to the AIDS condition, such as Kaposi 's sarcoma and Pneumo cystis carinii infection." Although sinusitis is not unique to the AIDS setting, otolaryngologists should be aware of the wide range of possible infectious etiologies in the HIV patient.
Many cases of HIV sinusitis are caused by common organisms. At least one study has shown that Streptococcus pneumoniae and Streptococcus viridans are the two most common causes of sinusitis in both the immunocompromised and immunocompetent patient populations.' However, the same study has also shown that HIV patients are more likely to suffer from sinusitis caused by the more atypical agents, such as Pseudomonas aeruginosa, Hemophilus influenza e, Staphylococcus aureus, coagulase-negative staphylococcus, Candida albicans, Klebsiella pneumoniae, Listeria monocytogenes, and Torulopsis (Candida) glabrata. In addition, rare atypical agents have also been described in the literature: cytomegalovirus," microsporidia," aspergillus? and other fungi," cryptosporidia," and amoebae."
We present the case of an AIDS patient who had sinusitis and subsequent disseminated infection caused by Acanthamoeba. To date , this is only the sixth reported case of sinusitis caused by this protozoan and the first described in the otolaryngology literature. Members of theAcanthamoeba genus are free-living protozoans.These organisms are common in the environment, and humans
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Eff ects onSteady-StateFexofenadlne Pharmacokinetics "There is no evidence thot doses higher thon the recommended dose ore more effective in relief of seasonal allergic rhinitis. often make cont act with them, usually without any ill effects. However, they have recentl y received much attention as a cause of Acanthamoeba keratitis in otherwise health y indi vidu als and oppor tunistic infections in immun ocomp romised patients. 10 Sinusitis is one exa mple of an opportunistic infection that can be caused by Aca nthamoeba: it is actually thought to be one of the predisposing conditions that might lead to a more serious disseminated disease state.
Case report
A 42-year-old man with AIDS (CDC subcategory C3) was admitted for dehydration secondary to intractable diarrhea of 3 days' duration. Prior to admis sion, the patient had experienced nasal congestion and discharge. Earlier examinations had revealed a pink , edematous nasal muco sa and left facial swelling. Computed tomography (CT) showed evidence of sinusitis in the left maxillary and ethmoid sinuses as well as an abscess in the left buccal soft tissues (fig ure I) . The abscess and sinusitis were addressed surgically. Using the Caldwell-Luc approach, biopsies and cultures of the left maxillary sinus tissue were collected and found to be positi ve for Aca nthamoeba ( figure 2 ). In addition, the patient had a history of Kaposi' s sarcoma, toxoplasmosis, Shigella enteritis, cytomega loviral retiniti s, and peripheral neurop athy. The patient' s medicati ons on admissi on included za lc ita bine , lami vud ine, sa qui nav ir, trimethoprim/ sulfamethoxa zole, clindamycin , ciprofloxa cin, ganciclovir, senna, naproxen, beclometh asone dipropi onate, oxym et azoline HCI, morphine, potassium chlorid e, warfarin , and zolpidem.
On admission, the patient had a temper ature of 100. physical examination was significant for left facial swelling, some erythematous lesions in the oral cavity with slight exudate, and multiple violaceou s plaque s on his skin that were consistent with Kaposi' s sarcoma. The rest of the examin ation was normal. Labor atory studies showed a sodiurn level of 136 mmol/ L, a potassium of 4.9 mmol/L, a chloride of 99 mmol/L, a bicarbonat e of23 mmollL, a BUN of 6 mg/dl , a creatinine of 0.5 mg/dl, and a glucose of 94 mg/dl. The patient had a white blood cell count of 11.6 x I03/JlI, a hemoglobin of8.7 g/dl, a hematocrit of25.2%, and a platelet count of 508 x I03/JlI. His serum and urine osmolalities were 259 and 35 1 mOsmlkg, respectively. His prothro mbin time was 14.4 seco nds, and his activated partial thromboplastin time was 73 seconds. The albumin level was 3 g/dl, total bilirubin was 0.6 mg/dl , and alkaline phosphatase was 147 lUlL. Assays for Clostridium difficile toxin s were negative.
To treat the Acanthamoeha infection, the patient was started on 200 mg of oral itracona zole twice a day and 450 mg of metronidazole intravenously every 6 hours. Six stool samples (two for bacteriology, two for parasitology, and two for acid-fast stainin g) were negati ve. On the third day of hospitalization, the patient began to spike fevers as high as 103 0 F. Blood , urine, and Mycobacterium avium 171 A intrace llulare cultures were negati ve. At this point, IV pentami dine was added to the anti-Acallthal/loeba regimen . A CT scan of the head and sinuses obtained on the fifth day of hospitalization revealed cha nges con sisten t with ea rly progressive multi focalleukoenceph alop athy. On the eleventh day of hospi talization , the patien t was obtunde nt and pro vided minim al res po nse to noxious stimuli. His chest x-ray at the time showed multiple rounded densiti es in both lun g fields ( figure 3 ). An arteria l blood gas sample showed a pH of7.52, Pc0 2 of32 mm Hg, a P0 2 of 53 mm Hg, a bicarbonate of 28 mmollL, and an 0 2satura tion of 90 %. At thi s point, a decision was made with the famil y to pur sue less agg ress ive managem ent , and a standing order of DO NOT RESUSC ITATE was posted . The patient died on the sixtee nth day of ho spit ali zation. The hospital obt ained co nse nt for an autopsy limited to the patient ' s lun g nodul es, the results of which were consis tent with an Acanthamoeba infecti on , acco rding to the path ology report.
Discussion
Causes. At least three fac tors help explain the predisposition of HIV patients to sinusitis. Acquired atopy. Th ese patient s are though t to have an acquire d atopic state, and sinusitis is included in thi s co nd itio n.I I It is believed that this atopic state is caused , at least in part , by the elevated levels of immunog lob ulin E see n in HIV patien ts. Thus, atop ic sinusi tis might help to cre ate a conditio n favora ble to an infec tious process.
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For over a quarter century we 've been prov id ing quality surgical and examination headlights and light sources know n for durability and value. Backed by unmatched customer service, our products have an indispu. Diminished mucoci liary cleara nce. These patie nts experience a reduction in the mucoci liary clearance of their sinuses.'? This decreased clearance contributes to the obstruction of the sinus ostia. The obstructed ostia ultimately help create an enviro nment that is favorable to pathogenic overgrowth. Although the exact mechanism has not been elucidated, other gro ups of immunocompromised patients (such as those who receive chemotherapy, irradiation, or bone marrow transplantation) have show n a similar decrease in mucoci liary cleara nce." These other immun ocomp romised patients, unlike HIV patie nts, regain their mucociliary clearance after their immune systems return to normal.
Low CD4 cell counts . It has been shown that the general depletion of CD4 T lymphocytes in HIV patients occurs in the nasal mucosa as well as elsewhere. 14Th e T lymph ocyte is the predo minant intraepi thelial cell in normal nasal mucosa .IS As the number of CD4 cells declines, the HIV patie nt incurs a grea ter risk of developing an infec tion in the sinus and/or respira tory tract.
These three factors help to exp lain the higher prevalence-up to 70%16-of sinusitis and its atypica l etiolo-. gies seen in HIV patie nts.
The disease process. Our patient was diagnosed with Acanthamoeba sinusitis by culture and biopsy. Species of the Acanthamoeba genus are protozoans who, during their life cycles, exist as two entities: the trophozoite and the cyst. The sizes of the trophozoites and cysts vary among the differen t species.'? These ubiquitous pathogens have been found not only in the air, but in fresh water, sea water, tap water, bottled minera l water, industrial cooli ng water, medicinal pools, chlorinate d swim ming pools, frozen swimming water, ocean sediment, air conditioners, dental treatment units, gastric lavage tubing, dialysis units, contact lenses, sewage, soil, and compost. 18 One study of healthy active-duty soldiers who were stationed in a dry, windy, and dusty region found that 15% of them had Acanthamoeba in their nasal mucosa. " This finding is consistent with beliefs about the proposed spread of infection in immunoco mpromise d patients. It is thought that after Acanthamoeba is firs t introduced into the skin and/or respiratory tract, it subsequently disseminates." Th is is what happened to our patient, whose cultures were posi tive for Aca nthamoeba in the left maxillary sinus before the pathogen spread to the lungs.
One uncommon, but almost always fatal, consequence
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Microline, Inc. , is extremely excited to introduce its NEW, fully rotational Offset Handp iece. This, along with our 54-mm scissors shaft and low-angled blades, w ill make ear surgery easier for YOU! of dissemination is multifocal encephalitis (granulomatous amebic encephalitis)." The CT scan of our patient's head suggests that such a central nervous system (CNS) infection was occurring at the time of his death.
Treatment. There is no single regimen that is believed to be effective against disseminatedA canthamo eba infections, and the prognosis is usually poor . There have been only two reports of successfu l treatment-one with a combination ofIV pentamidine and oral itraconazole and the other with 5-fluorocytosine.
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Both patients were immunocompromised with disseminated infection, but with no CNS involvement.
The regimen for our patient-pentamidine, itraconazole, and metronidazo le-was not successfu l in eradicating the infection . Although in vitro studies have yielded varying results, they have provided us with a list of effective and possibly effective anti-Acanthamoeba medications. These drugs include neomycin sulfate, paromomycin, natamycin, ketoconazole, ciclopirox olamine;" pentamidine isethionate, propamidine isethionate, stilbamidine isethionate," amphotericin B, sulfadiazine, sulfisoxazole, sulfamethoxazole, polymyxin Band E, 25 and clotrimazole."
Treatment for the sinusitis component of HIV infection is important and consists of eradicating the infection and providing symptomatic relief. Our patient was given beclomethasone and oxymetazoline for relief of nasal congestion. Long-term use of topical steroids has not increased the rates of opportunistic infections and it is safe when used properly ." Although topical decongestants are generally not recommended for chronic sinusitis," our patient experienced symptomatic relief with oxymetazoline during an acute exacerbation. Some patients with HIV sinusitis might benefit from a mucolytic agent such as guaifenesin, owing to the thick and tenacious nature of their mucus ."
When conve ntional methods fail to relieve symptoms, endoscopic sinus surgery can often offer palliation. Although sinus surgery has not been as successful in curing sinus disease in HIV patients as it is in the normal population, it definitely improves their quality of life." The refractory nature of HIV sinusitis to surgery was evident in our patient, who still had sinus disease following sinus surgery .
As the number of cases of AIDS and HIV infection continues to increase , active research for better treatment options is ongoing . This research will undoubtedly result in longer survival and less morbidity .
